Tafinlar

(dabrafenib)
dabrafenib 50 MG Oral Capsule [Tafinlar]dabrafenib 75 MG Oral Capsule [Tafinlar]
NO BOXED WARNING

Dosage & administration

drug label

Tafinlar prescribing information

financial assistance

Tafinlar financial assistance options

Co-pay savings program

commercial only
Enroll in Patient Savings Program - Mekinist
Enroll in Patient Savings Program - Tafinlar
Enroll in Patient Savings Program - Tafinlar + Mekinist
Learn More

Foundation programs

under insured
no insurance
goverment insurance
65+
PANO Service Request Form - Patient
PANO Service Request Form - HCP
PANO Service Request Form - Tafinlar + Mekinist (PDF): HCP
PANO Service Request Form - Tafinlar (PDF): HCP
PANO Service Request Form - Mekinist (PDF): HCP
Learn More

PubMed™ | Tafinlar

Tafinlar PubMed™ News

patient education

Tafinlar patient education

To share resource; ask patient to:
1.Pull out phone
2.Open camera
3.Scan QR code with camera
4.Tap link

Patient toolkit

About Taflinlar + Mekinist: BRAF+ Melanoma
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
View How to Take Tafinlar + Mekinist: BRAF+ Melanoma
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Side Effects: BRAF+ Melanoma
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Patient Resources: BRAF+ Melanoma
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Caregiver Resources: BRAF+ Melanoma
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Patient Stories: BRAF+ Melanoma
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Patient Brochure: BRAF+ Melanoma
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Patient Brochure: Metastatic Non-Small Cell Lung Cancer (NSCLC) With BRAF V600E Mutation
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
About Tafinlar + Mekinist: Metastatic Non-Small Cell Lung Cancer (NSCLC) With BRAF V600E Mutation
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
View How to Take Tafinlar + Mekinist: Metastatic Non-Small Cell Lung Cancer (NSCLC) With BRAF V600E Mutation
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Side Effects: Metastatic Non-Small Cell Lung Cancer (NSCLC) With BRAF V600E Mutation
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Managing Side Effects: Metastatic Non-Small Cell Lung Cancer (NSCLC) With BRAF V600E Mutation
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Doctor Discussion Guide: Metastatic Non-Small Cell Lung Cancer (NSCLC) With BRAF V600E Mutation
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Patient Resources: Metastatic Non-Small Cell Lung Cancer (NSCLC) With BRAF V600E Mutation
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Fever Management Brochure
ASK PATIENT TO:
Open Camera on Phone
Scan QR Code & Tap Link
Learn More

people also ask

Tafinlar FAQs

Is Tafinlar safe to use during pregnancy?Tafinlar can cause harm to a fetus when administered to a pregnant woman. Limited data in pregnant women exists. Animal studies showed developmental toxicity at doses greater than human exposure at the recommended clinical dose. Pregnant women should be informed of the potential risks.
Are there risks associated with breastfeeding while using Tafinlar?There is no data available on the presence of Tafinlar in human milk or its effects on breastfed infants or milk production. Due to potential adverse reactions, women are advised not to breastfeed during Tafinlar treatment and for 2 weeks after the last dose.
What precautions should be taken for females and males of reproductive potential using Tafinlar?Females of reproductive potential should undergo pregnancy testing before initiating Tafinlar. Effective contraception is advised during treatment and for 2 weeks after the last dose. Non-hormonal contraception methods are recommended due to potential interactions. Male patients with female partners of reproductive potential should use condoms during treatment and for 2 weeks after the last dose to prevent drug exposure.
Is Tafinlar used in pediatric patients?Tafinlar, in combination with trametinib, is approved for pediatric patients (1 year and older) with specific solid tumors and BRAF V600E mutations, as well as those with LGG and BRAF V600E mutations requiring systemic therapy. Safety and effectiveness have been established in pediatric patients based on studies that enrolled various age groups.
What data is available regarding geriatric use of Tafinlar?Clinical studies included elderly patients in various tumor types receiving Tafinlar, either alone or in combination. No significant differences in effectiveness or safety were observed between geriatric patients and younger adults in these studies, except for increased incidences of certain side effects in some cases.
Is there a recommended dosage adjustment for patients with hepatic impairment?For patients with mild hepatic impairment, no dosage adjustment is recommended. However, those with moderate to severe hepatic impairment may experience increased exposure to Tafinlar due to altered metabolism. No specific dosage recommendation has been established for these patients.
FAQ Data Source